Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer

被引：1
|
作者：
Takeda, Masayuki [1 ]
Watanabe, Satomi [1 ]
Rothenberg, S. Michael [2 ]
Kherani, Jennifer [2 ]
French, Pearl P. [3 ]
Olek, Elizabeth [2 ]
机构：
[1] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan
[2] Loxo Oncol Inc, Stamford, CT USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-5236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5236
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    Hendriks, Lizza E. L.
    Zhou, Caicun
    Solomon, Benjamin
    Perol, Maurice
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (04): : 381 - 382
  • [22] Activity of selpercatinib in RET fusion-positive cancers confirmed
    Diana Romero
    Nature Reviews Clinical Oncology, 2022, 19 : 747 - 747
  • [23] Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC
    Tina Nie
    Yahiya Y. Syed
    Targeted Oncology, 2023, 18 : 169 - 176
  • [24] Activity of selpercatinib in RET fusion-positive cancers confirmed
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (12) : 747 - 747
  • [25] Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC
    Nie, Tina
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2023, 18 (01) : 169 - 176
  • [26] Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
    Drilon, A.
    Oxnard, G.
    Wirth, L.
    Besse, B.
    Gautschi, O.
    Tan, S. W. D.
    Loong, H.
    Bauer, T.
    Kim, Y. J.
    Horiike, A.
    Park, K.
    Shah, M.
    McCoach, C.
    Bazhenova, L.
    Seto, T.
    Brose, M.
    Pennell, N.
    Weiss, J.
    Matos, I.
    Peled, N.
    Cho, B. C.
    Ohe, Y.
    Reckamp, K.
    Boni, V.
    Satouchi, M.
    Falchook, G.
    Akerley, W.
    Daga, H.
    Sakamoto, T.
    Patel, J.
    Lakhani, N.
    Barlesi, F.
    Burkard, M.
    Zhu, V.
    Garcia, V. Moreno
    Medioni, J.
    Matrana, M.
    Rolfo, C.
    Lee, D. H.
    Nechushtan, H.
    Johnson, M.
    Velcheti, V.
    Nishio, M.
    Toyozawa, R.
    Ohashi, K.
    Song, L.
    Han, J.
    Spira, A.
    De Braud, F.
    Rohrberg, K. Staal
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S6 - S7
  • [27] Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
    Yokota, Tomoya
    CASE REPORTS IN ONCOLOGY, 2022, 15 (03): : 833 - 840
  • [28] Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
    Rosen, Ezra Y.
    Johnson, Melissa L.
    Clifford, Sarah E.
    Somwar, Romel
    Kherani, Jennifer F.
    Son, Jieun
    Bertram, Arrien A.
    Davare, Monika A.
    Gladstone, Eric
    Ivanova, Elena, V
    Henry, Dahlia N.
    Kelley, Elaine M.
    Lin, Mika
    Milan, Marina S. D.
    Nair, Binoj C.
    Olek, Elizabeth A.
    Scanlon, Jenna E.
    Vojnic, Morana
    Ebata, Kevin
    Hechtman, Jaclyn F.
    Li, Bob T.
    Sholl, Lynette M.
    Taylor, Barry S.
    Ladanyi, Marc
    Janne, Pasi A.
    Rothenberg, S. Michael
    Drilon, Alexander
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 34 - 42
  • [29] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
    Drilon, A.
    Oxnard, G. R.
    Tan, D. S. W.
    Loong, H. H. F.
    Johnson, M.
    Gainor, J.
    McCoach, C. E.
    Gautschi, O.
    Besse, B.
    Cho, B. C.
    Peled, N.
    Weiss, J.
    Kim, Y. -J.
    Ohe, Y.
    Nishio, M.
    Park, K.
    Patel, J.
    Seto, T.
    Sakamoto, T.
    Rosen, E.
    Shah, M. H.
    Barlesi, F.
    Cassier, P. A.
    Bazhenova, L.
    De Braud, F.
    Garralda, E.
    Velcheti, V.
    Satouchi, M.
    Ohashi, K.
    Pennell, N. A.
    Reckamp, K. L.
    Dy, G. K.
    Wolf, J.
    Solomon, B.
    Falchook, G.
    Ebata, K.
    Nguyen, M.
    Nair, B.
    Zhu, E. Y.
    Yang, L.
    Huang, X.
    Olek, E.
    Rothenberg, S. M.
    Goto, K.
    Subbiah, V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 813 - 824
  • [30] Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report
    Arora, Aakriti
    Zaemes, Jacob
    Ozdemirli, Metin
    Kim, Chul
    FRONTIERS IN ONCOLOGY, 2023, 13
12345